Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

I-Mab ADR (NQ: IMAB )

1.420 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 1.420
Bid (Size) 1.350 (10)
Ask (Size) 1.520 (6)
Prev. Close 1.420
Today's Range 1.420 - 1.420
52wk Range 1.170 - 3.038
Shares Outstanding 185,613,662
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-36.89%
-36.89%
1 Month
-17.44%
-17.44%
3 Month
-21.11%
-21.11%
6 Month
-14.97%
-14.97%
1 Year
-49.82%
-49.82%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
(IMAB) - Analyzing I-MAB's Short Interest
Via Benzinga
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Looking Into I-MAB's Recent Short Interest
Via Benzinga
Expert Ratings for I-MAB
Via Benzinga
Where I-MAB Stands With Analysts
Via Benzinga
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
Via Talk Markets
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Analyst Ratings for I-MAB
Via Benzinga
5 Analysts Have This to Say About I-MAB
Via Benzinga
I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Via Talk Markets
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
Via InvestorPlace
Why Is TRACON Pharma (TCON) Stock Down 51% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Last Day Of Q1
Via Benzinga
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.